Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort
Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort
复制标题
DOI：
10.1007/s00415-019-09348-3
复制
发表时间：
2019-08-01
影响因子：
6
通讯作者：
Cano, Stefan
中科院分区：
文献类型：
--
作者：
Regnault, Antoine;Boroojerdi, Babak;Cano, Stefan
目的开发帕金森病（PD）的疾病修饰疗法需要关注早期疾病进展特征的结局测量策略。我们探索了在此背景下使用运动障碍协会统一帕金森病评定量表（MDS-UPDRS）第II部分（患者日常生活的运动体验）和第III部分（临床医生运动检查）的心理测量学证据。方法MDS-UPDRS-II和-III数据在筛选时收集，第12个月和第24个月来自384名早期PD患者（诊断
Objectives Developing disease modifying therapies for Parkinson's disease (PD) calls for outcome measurement strategies focused on characterizing early stage disease progression. We explored the psychometric evidence for using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part II (patient motor experience of daily living) and part III (clinician motor examination) in this context.Methods MDS-UPDRS-II and -III data were collected at screening, month 12, and month 24 from 384 early stage PD patients (diagnosis